LND topic: recursion-pharmaceuticals page 1

recursion pharmaceuticals

Ligand’s Stock Rises After Bank of America Adds a Buy Rating

March 11, 2026

Bank of America has added Ligand Pharmaceuticals to its list of stocks it recommends buying, setting a new price target at $244. The move comes as the bank highlights Ligand’s business model, which focuses on high‑margin products and a lower level of risk compared to many other biopharma companies.

business

Drug Companies Scramble to Join Trump's Pricing Plan

February 12, 2026

Pharmaceutical firms not included in President Trump's drug pricing agreements are now trying to negotiate their own deals. This move is aimed at avoiding potential tariffs and new pricing regulations. Industry insiders reveal that these companies are reaching out to the White House and Medicare off

environment

America's Hidden Poison: The Truth About Farmland and Sewage Sludge

January 23, 2026

America's farmlands are facing a serious issue. Sewage sludge, often called "biosolids, " is being spread on fields as fertilizer. This sludge contains harmful chemicals and waste from homes and industries. The EPA allows this practice through a rule called the 503 rule. This rule does not make the

politics

Trade Tensions Rise: US Official Suggests EU Should Handle Greenland Tariff Issue Independently

January 18, 2026

The U. S. has a message for Europe: deal with Greenland tariffs on your own. Jamieson Greer, the U. S. Trade Representative, said it's Europe's call whether to tie the Greenland issue to their trade deal with the U. S. He made these remarks at the Detroit Auto Show, suggesting Europe should separate

business

Pharma's Future: How Contract Manufacturing is Changing the Game

January 16, 2026

The world of pharmaceuticals is changing fast. Companies are teaming up to innovate, strengthen their supply chains, and get their products to market. This shift is big news, and it's important for anyone making decisions in this field to stay informed. The market for contract manufacturing in phar

health

Bright Hope: New Brain Treatment Offers Relief for Depression

January 15, 2026

Depression can be a heavy fog that clouds the mind and makes simple tasks feel impossible. For years, Valerie Zeko felt this fog, struggling with a condition that made her feel like her life was falling apart. She tried different antidepressants, but they either didn't work or caused more problems,

health

A New Leader Joins the Fight Against Cancer

January 15, 2026

ViroMissile, Inc. has welcomed Michael G. Wood as their new Chief Business Officer. This move is big news for the company, which is working on a new way to fight cancer using viruses. Wood's job will be to help the company grow, find money for projects, and make important deals. Wood has a lot of e

environment

Pollution in Eswatini's Waters: A Hidden Threat

January 10, 2026

Eswatini's waters are under threat from a silent invader: emerging pollutants (EMPs). These pollutants, often overlooked, can harm both people and wildlife. A recent study took a closer look at these EMPs in the country's wastewater and rivers. Using advanced technology, researchers identified 347 d

finance

South Korea's Bold Move to Boost Currency Market

January 9, 2026

South Korea is taking a big step to make its currency market more open. Starting in July, the country will allow trading 24 hours a day. This change is part of a bigger plan to make the Korean won more accessible worldwide. The goal is to attract more investors and increase demand for the currency. ...

business

A New Era for MannKind: What's Next in 2026?

January 8, 2026

MannKind, a company focused on treating long-term illnesses, had a strong finish to 2025. They acquired another company, scPharmaceuticals, and made over $100 million in their last quarter. This success has set the stage for an exciting 2026, with two major products potentially hitting the market.